PubMed Health⌕ Search

Biomedical subjects

Kohei Ota

Publications and source records attributed to Kohei Ota.

3 recordsLinked to original sources

Synaptic Mitochondrial Oxidative Stress Contributes to Individual Variability in Age-Related Cognitive Inflexibility in Mice.

Aging is associated with impairments in cognitive flexibility, a key executive function supported by the medial prefrontal cortex (mPFC), yet the biological mechanisms underlying individual variability in age-related decline remain poorly understood. Here we investigated behavioral, ultrastructural, and proteomic correlates of cognitive inflexibility in mice across aging. Using a touchscreen-based attentional set-shifting task, we observed substantial individual variability in cognitive inflexibility among aged C57BL/6J mice. Volume electron microscopy of the mPFC revealed age-related reductions in synaptic density, but these structural changes did not correlate with cognitive performance. Instead, the proportion of synapses containing presynaptic mitochondria was inversely associated with cognitive flexibility in aged mice. To identify molecular correlates, we performed proteomic profiling of mPFC whole tissue and synaptosome fractions. Proteins associated with individual variability in cognitive inflexibility were largely distinct from those associated with chronological aging. Notably, synaptosomal proteins negatively correlated with cognitive performance were strongly enriched for mitochondrial pathways, including oxidative phosphorylation, mitochondrial translation, and the tricarboxylic acid cycle. Consistent with these findings, the mitochondria-targeted antioxidant MitoQ improved attentional set-shifting performance in aged mice without affecting initial learning. Proteomic analyses revealed that MitoQ reduced the abundance of synaptosomal mitochondrial proteins, particularly those involved in mitochondrial apoptotic signaling. Together, these results suggest that synaptic mitochondrial oxidative stress in the mPFC contributes to individual vulnerability to cognitive inflexibility. Targeting synaptic mitochondrial oxidative stress may therefore represent a promising strategy to preserve executive function during aging.

Animals↗

Microarray analysis identifies interferon beta-regulated genes in multiple sclerosis.

The molecular mechanisms for the interferon beta (IFNbeta) treatment of multiple sclerosis (MS) remain to be characterized. Using cDNA microarray technology, we have compared the gene expression profile of T and non-T cells derived from relapsing-remitting MS before and after treatment with IFNbeta-1b. IFNbeta treatment significantly altered expression of 21 genes out of 1263 at 3 and 6 months after treatment. These genes included nine with IFN-responsive promoter elements. Whereas there was no change in Th1 or Th2 marker genes, some of the changes were unexpected but coincided with the beneficial effect of IFNbeta in MS.

Adult↗

[Intravenous immunoglobulin in multiple sclerosis].

Intravenous immunoglobulin(IVIg) is a immunomodulating therapy to administer a relatively high dose of human immunoglobulins to a number of autoimmune diseases. Clinical trials of IVIg for neurological disorders including autoimmune peripheral neuropathy were carried out since the later of 1980's, and the efficacy of IVIg for such diseases was proved. In recent years the effectiveness of IVIg for multiple sclerosis(MS) has been reported in several randomized controlled trials(RCTs). MS patients in the trials were given immunoglobulin or placebo every month or two months for more than half a year. IVIg in particular is beneficial in prevention a recurrence of relapsing remitting MS and in improvement of MRI findings in a part of RCTs. However, IVIg does not recognize the distinct effectiveness in progression of secondary progressive MS yet. Some problems, for example, optimal dose or dosage frequency are unsolved. Generally a adverse effect of IVIg in MS patient is slightness and the continuation treatment of IVIg is tolerate for most patients. Now, in Europe where a clinical trial goes ahead, IVIg might be considered the therapy for MS when a already established treatment for MS such as interferon--beta is not effective or not be able to use. On the other hand, unfortunately the effectiveness of IVIg for MS could not be recognized by RCT executed in Japan.

Humans↗